Robert Baumgartner V - 27 Oct 2022 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Reporting relationship: Director
Issuer ticker: TECH
Reported as of: 27 Oct 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Oct 2022, 17:22:44 UTC
Prior SEC filing: 11 May 2022
Next SEC filing: 30 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ Brenda S. Furlow as Attorney-in-Fact for Robert V. Baumgartner pursuant to Power of Attorney previously filed.

Key filing fact

Robert Baumgartner V filed Form 4 for BIO-TECHNE Corp (TECH) on 31 Oct 2022.

Key facts

This page summarizes Robert Baumgartner V's Form 4 filing for BIO-TECHNE Corp (TECH).
2 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 31 Oct 2022, 17:22.

Change

Previous filing in this sequence was filed on 11 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TECH transaction

Common Stock

Award

Transaction value: $0
Shares: +338
Change %: +3.3%
Price: $0.000000
Shares after: 10,444
Date: 27 Oct 2022
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TECH transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +865
Change %
Price: $0.000000
Shares after: 865
Date: 27 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 865
Exercise price: $295.77
Footnotes: F1

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,507
Date: 27 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,507
Exercise price: $255.69

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 633
Date: 27 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 633
Exercise price: $515.24

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,985
Date: 27 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,985
Exercise price: $101.19

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,125
Date: 27 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,125
Exercise price: $125.05

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,898
Date: 27 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,898
Exercise price: $179.84

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,011
Date: 27 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,011
Exercise price: $201.64

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,000
Date: 27 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,000
Exercise price: $91.78

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,260
Date: 27 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,260
Exercise price: $87.34

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .